A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia
Latest Information Update: 28 May 2025
At a glance
- Drugs Ziftomenib (Primary) ; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 13 Mar 2025 Planned initiation date changed from 1 Feb 2025 to 1 Mar 2025.
- 13 Mar 2025 Status changed from not yet recruiting to recruiting.
- 27 Jan 2025 Planned End Date changed from 1 Oct 2026 to 1 Jan 2027.